Markus Rießland

2.8k total citations
32 papers, 1.6k citations indexed

About

Markus Rießland is a scholar working on Molecular Biology, Genetics and Physiology. According to data from OpenAlex, Markus Rießland has authored 32 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 18 papers in Genetics and 10 papers in Physiology. Recurrent topics in Markus Rießland's work include Neurogenetic and Muscular Disorders Research (18 papers), RNA modifications and cancer (14 papers) and Telomeres, Telomerase, and Senescence (7 papers). Markus Rießland is often cited by papers focused on Neurogenetic and Muscular Disorders Research (18 papers), RNA modifications and cancer (14 papers) and Telomeres, Telomerase, and Senescence (7 papers). Markus Rießland collaborates with scholars based in Germany, United States and Poland. Markus Rießland's co-authors include Brunhilde Wirth, Eric Hahnen, Lutz Garbes, Ingmar Blümcke, Lars Brichta, Jan Hauke, Ilker Y. Eyüpoglu, Miriam Peters, Ylva Mende and Julia Schreml and has published in prestigious journals such as Cell, Nature Communications and Brain.

In The Last Decade

Markus Rießland

32 papers receiving 1.6k citations

Peers

Countries citing papers authored by Markus Rießland

Since Specialization

Citations

This map shows the geographic impact of Markus Rießland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Rießland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Rießland more than expected).

Fields of papers citing papers by Markus Rießland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Rießland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Rießland. The network helps show where Markus Rießland may publish in the future.

Co-authorship network of co-authors of Markus Rießland

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Rießland. A scholar is included among the top collaborators of Markus Rießland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Rießland. Markus Rießland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nuclear Import Defects Drive Cell Cycle Dysregulation in Neurodegeneration 2025 ·Aging Cell ·(unknown), (unknown), Markus Rießland, Roger B. Sher	3
2	Systematic profiling reveals distinct senescence signatures and regulators across human brain cell types 2025 ·Nature Communications ·(unknown), (unknown), Roger B. Sher, Markus Rießland	1
3	Therapeutic targeting of senescent cells in the CNS 2024 ·Nature Reviews Drug Discovery ·Markus Rießland, Methodios Ximerakis, Andrew A. Jarjour, Bin Zhang, Miranda E. Orr	20
4	The SATB1‐MIR22‐GBA axis mediates glucocerebroside accumulation inducing a cellular senescence‐like phenotype in dopaminergic neurons 2024 ·Aging Cell ·(unknown), Benjamin Kolisnyk, (unknown), (unknown), Tae Wan Kim, (unknown), (unknown), (unknown), Emily J. Park, Roger B. Sher, Lorenz Studer, Markus Rießland	16
5	Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics 2023 ·The Journal of Prevention of Alzheimer s Disease ·Markus Rießland, Miranda E. Orr	23
6	Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons 2019 ·Cell stem cell ·Markus Rießland, Benjamin Kolisnyk, Tae Wan Kim, Jia Cheng, (unknown), (unknown), Emily J. Park, (unknown), Devrim Acehan, Lavoisier Ramos‐Espiritu, Wei Wang, Jack Zhang, Jaewon Shim, Gabriele Ciceri, Lars Brichta, Lorenz Studer, Paul Greengard	124
7	CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis 2018 ·Brain ·(unknown), Natalia Mendoza-Ferreira, Seyyedmohsen Hosseinibarkooie, Svenja Schneider, (unknown), (unknown), (unknown), Markus Rießland, Matthias Hammerschmidt, Frank Rigo, C. Frank Bennett, Min Jeong Kye, Laura Torres‐Benito, Brunhilde Wirth	46
8	The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype 2016 ·The American Journal of Human Genetics ·Seyyedmohsen Hosseinibarkooie, Miriam Peters, Laura Torres‐Benito, Raphael H. Rastetter, (unknown), Andrea Hoffmann, Natalia Mendoza-Ferreira, Anna Kaczmarek, (unknown), (unknown), Tobias Lamkemeyer, Frank Rigo, C. Frank Bennett, Christoph Guschlbauer, Ansgar Büschges, Matthias Hammerschmidt, Markus Rießland, Min Jeong Kye, Christoph S. Clemen, Brunhilde Wirth	125
9	SMN regulates axonal local translation via miR-183/mTOR pathway 2014 ·Human Molecular Genetics ·Min Jeong Kye, (unknown), Mary H. Wertz, (unknown), Bikem Akten, (unknown), Miriam Peters, Markus Rießland, Pierre Neveu, Brunhilde Wirth, Kenneth S. Kosik, S. Pablo Sardi, Umrao R. Monani, Marco A. Passini, Mustafa Şahin	118
10	Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy 2013 ·Neuroscience Letters ·Eilidh Somers, Markus Rießland, Julia Schreml, Brunhilde Wirth, Thomas H. Gillingwater, Simon H. Parson	10
11	How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches 2013 ·Current Opinion in Genetics & Development ·Brunhilde Wirth, Lutz Garbes, Markus Rießland	72
12	Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585 2012 ·European Journal of Human Genetics ·Julia Schreml, Markus Rießland, (unknown), Lutz Garbes, (unknown), (unknown), Jan S. Kramer, Eilidh Somers, Simon H. Parson, Raoul Heller, Albrecht Berkessel, Anja Sterner‐Kock, Brunhilde Wirth	60
13	Reversible molecular pathology of skeletal muscle in spinal muscular atrophy 2011 ·Human Molecular Genetics ·Chantal A. Mutsaers, Thomas M. Wishart, Douglas J. Lamont, Markus Rießland, Julia Schreml, Laura H. Comley, Lyndsay M. Murray, Simon H. Parson, Hanns Lochmüller, Brunhilde Wirth, Kevin Talbot, Thomas H. Gillingwater	79
14	SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy 2010 ·Human Molecular Genetics ·Markus Rießland, (unknown), Anja Förster, (unknown), Jan Hauke, Lutz Garbes, (unknown), Ylva Mende, Ingmar Blümcke, Eric Hahnen, Brunhilde Wirth	177
15	Deficiency of the splicing factor Sfrs10 results in early embryonic lethality in mice and has no impact on full-length SMN/Smn splicing 2010 ·Human Molecular Genetics ·Ylva Mende, (unknown), Markus Rießland, Frank J. Schoenen, (unknown), André Kleinridders, Christoph Köhler, Thorsten Buch, Brunhilde Wirth	47
16	LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate 2009 ·Human Molecular Genetics ·Lutz Garbes, Markus Rießland, Irmgard Hölker, Raoul Heller, Jan Hauke, Christian Tränkle, Roland Coras, Ingmar Blümcke, Eric Hahnen, Brunhilde Wirth	87
17	Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition 2008 ·Human Molecular Genetics ·Jan Hauke, Markus Rießland, Sebastian Lunke, Ilker Y. Eyüpoglu, Ingmar Blümcke, Assam El‐Osta, Brunhilde Wirth, Eric Hahnen	111
18	Drug discovery for spinal muscular atrophy 2007 ·Expert Opinion on Drug Discovery ·Brunhilde Wirth, Markus Rießland, Eric Hahnen	3
19	The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells 2006 ·Human Genetics ·Markus Rießland, Lars Brichta, Eric Hahnen, Brunhilde Wirth	104
20	In vitro and ex vivo evaluation of second‐generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy 2006 ·Journal of Neurochemistry ·Eric Hahnen, Ilker Y. Eyüpoglu, Lars Brichta, Kirsten Haastert‐Talini, Christian Tränkle, Florian A. Siebzehnrübl, Markus Rießland, Irmgard Hölker, Peter Claus, J. Romstöck, Rolf Buslei, Brunhilde Wirth, Ingmar Blümcke	126

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact